Recently, Changchun High-tech Industry (Group) Co., Ltd. (hereinafter referred to as "the Company") has received notification from the U.S. Food and Drug Administration (hereinafter referred to as "FDA") regarding the approval documents for the clinical trial application of GenSci136, as follows:
000661SZSE
🚨 Material Event
Announcement on Approval of Clinical Trial Application for GenSci136
✨ AI Summary
The announcement details that Changchun High-tech Industry (Group) Co., Ltd. has received approval from the FDA for the clinical trial application of GenSci136. The application was submitted by Changchun Jinshang Pharmaceutical Co., Ltd. under IND number 179962. GenSci136 is intended for the treatment of myasthenia gravis (MG). The company emphasizes the ongoing development of related projects.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.